argenx N.V.'s rare disease drug Vyvgart has flown out of the blocks following the therapy's recent approval in the US for generalized myasthenia gravis (gMG), with sales in the first quarter smashing analyst forecasts.
The US Food and Drug Administration gave the green light to Vyvgart (efgartigimod), Argenx’s first approved product, on 17 December...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?